Table 3.

Clinical results.

Study	Follow up (month)	MST (months)	Type for RT	Patients (n)	1-year OS (%)	2-year OS (%)	Responser (n)	CR (%)	PR (%)	SD (%)	PD (%)	ORR (%)	LCR (%)
Hou et al.	10		CRT	181			181	29.3	31.5	33.7	5.5	60.8	94.5
Tan et al.	14.3	8	CRT	26	23	4	26	8	31	61		39
Toya et al.		9.6	CRT	38	39.4	17.5	38	15.8	28.9	44.7	10.5	44.7	89.4
Igaki et al.		5.6	CRT	18	33.3	9	12	16.7	16.7	58.3	8.3	33.4	91.7
Tanaka et al.		9.4	CRT	67	39	9	67	7.5	37.3	23.9	31.3	44.8	68.7
Okazaki et al.	5.3	6.4	CRT	56			50	0	22	44	34	22	66
Iwamoto et al.		13.3	CRT	80	56	26.7
Yu et al.	8	11.6	CRT	281	48.1	26.9	260	3.85	54.23	27.69	14.23	58.08	85.77
Rim et al.		13.9	CRT	45	51.5		45	6.7	55.6	31	6.7	62.3	93.3
Bae et al.	8		CRT	47	15	15	47	0	40	51	9	40	91
Huang et al.		3.8	CRT	326	16.7	5.5
Yeh et al.	10	7	CRT	106	34.7	11	106	9.5	52	33	5.5	61.5	94.5
Pao et al.	4.4	6.6	CRT	42	30	19	27	14.8	59.3	25.9	0	74.1	100
Onishi et al.		12.4	CRT+HAIC	33	54.5	22	31	3.2	45.2	45.2	6.5	48.4	93.6
Kodama et al.		9.9	CRT+HAIC	36	47	20.3	36	8.3	41.7	50	0	50	100
Han et al.		13.5	CRT+HAIC	152	60	29.5	152	1.3	46.7	34.2	17.8	48	82.2
Tang et al.	10.7	12.3	CRT+TACE	185	51.6	28.4
Lu et al.		13.02	CRT+TACE	30	62.4	20.81	30	16.7	53.3	20	10	70	90
Yamada et al.		7	CRT+TACE	19	40.6	10.2	19	0	57.9	42.1	0	57.9	100
Shirai et al.	9.4	10.3	CRT+TACE	19	47.4	23.7	19	0	36.8	52.6	10.5	36.8	89.4
Yoon et al.	10.6	10.6	CRT+TACE	412	42.5	22.8	409	6.6	33	46	14.4	39.6	85.6
Yoon et al.		12.8	CRT+TACE	45	53.3	26.8	45	0	28.9	51.1	20	28.9	80
Yu et al.	11.4		CRT+TACE +hyperthermia	69	85	62.9	69	34	36.2	15.3	14.5	70.2	85.5
Sugahara et al.	21	22	PRT	35	68	48	35	22.8	60	8.6	8.6	82.8	91.4
Hashimoto et al.	8.4		PRT	34	55		34	15	47	35	3	62	97
Komatsu et al.			PRT	31	47	24
Sekino et al.	21		PRT	21	62	33
Lee et al.	13.2	13.2	PRT	27	55.6	33.3	27	0	55.6	37	7.4	55.6	92.6
Kim et al.	15.2	34.4	PRT	41	73.2	51.1	41	34.2	48.8	14.3	2.4	83	97.3
Xi et al.	10	13	SBRT	41	50.3		41	36.6	39	17.1	7.3	75.6	92.7
Shui et al.	9.5	10	SBRT	70	40		62	9.7	69.4	6.4	14.5	79.1	85.5
Lou et al.		10	SBRT	75	38.7	13.3	75	22.7	73.3	4	0	96	100
Dutta et al.	6	11.4 (mean)	SBRT	72	38	10	54	0	36	42	22	36	78
Kumar et al.	8	15	SBRT	29	60		29	7	80	13		87
Wang et al.	7.4	9.6 (mean)	SBRT	20	58		22	36.4	31.8	27.3	4.4	68.2	95.5
Choi et al.	8.4	20.8	SBRT	24	67.5	48.2	24	8.3	45.8	29.2	16.7	54.1	83.3
Hou et al.	11.8	10.46	CRT	64	35.8	16	64	1.6	51.6	12.5	34.3	53.2	65.7
		15.47	CRT	54	59.3	32	54	5.6	64.8	9.3	20.3	70.4	79.7
Zhao et al.	13	19	CRT+TACE+Sorafenib	28	72.4	48	28	10.7	35.7	28.6	25	46.4	75
	14.1	15.2	CRT+TACE	35	77.5	16	35	0	45.7	31.4	22.9	45.7	77.1
Li et al.	31	10	CRT	154	48.1	25.1
		10	SBRT	133	46.5	29.3
Nomura et al.		6.7	CRT+HAIC	18	21	6	32	9.4	50	21.9	18.7	59.4	81.3
		49.2	CRT+HAIC+Sorafenib	14	75	50
Lin et al.		6	SBRT	22			14	7	71	21	0	78	100
		6.7	CRT	21
Yang et al.		10.9	SBRT	54	34.9	15.3	45	11.1	51.1	33.33	4.4	62.2	95.53
		4.7	CRT	86	15.7	8	59	8.5	25.4	45.8	20.3	33.9	79.7
Que et al.	13.22 (mean)	12.5	SBRT+Sorafenib	18	55.6	17.7	18	33.33	44.44	11.11	11.11	77.77	88.88
	15.33 (mean)	7	SBRT	36	33.3	11.1	36	25	50	2.78	22.22	75	77.78
Khorprasert et al.	8.2	7.9	CRT	140	39.1	16.5	119	18.5	55.5	8.4	17.6	74	82.4
		11.9	SBRT	20	45	22

Red font means overall survival in 1st year; overall survival in 2nd year.